Drugs and vascular dementia

Dementia and Geriatric Cognitive Disorders

Volumn 16, Issue 1, 2003, Pages 1-6

  Allain, Hervé ^a   Bentue Ferrer, Danièle ^a   Tribut, Olivier ^a   Pinel, Jean François ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Acetylcholinesterase inhibitors; Pharmacology; Prevention; Vascular dementia

Indexed keywords

1 (2 CYANOETHYL) 1,2,3,6 TETRAHYDRO 4 (3 TRIFLUOROMETHYLPHENYL)PYRIDINE; ACETYLSALICYLIC ACID; AGI 4207; AJMALICINE; AJMALICINE PLUS ALMITRINE; ALMITRINE DIMESILATE; ANIRACETAM; BROMOCRIPTINE MESILATE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DENBUFYLLINE; DIHYDROERGOTOXINE MESILATE; DIPYRIDAMOLE; DONEPEZIL; EBIXAN; ERGOT ALKALOID; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NICARDIPINE; NICERGOLINE; NIMODIPINE; NOOTROPIC AGENT; OXIRACETAM; PENTOXIFYLLINE; PERINDOPRIL; PIRACETAM; PIRIBEDIL; POSATIRELIN; PROBUCOL SUCCINATE; PROPENTOFYLLINE; PRS 21 1092; RIVASTIGMINE; SPC 9766; SULODEXIDE; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; XANTHINE DERIVATIVE;

AMNESIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APATHY; APHASIA; BRAIN PROTECTION; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CELL DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOXIC CELL; LEUKOARAIOSIS; LIFESTYLE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NEUROTRANSMISSION; PALLIATIVE THERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 0037262479     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069986     Document Type: Review

References (68)

1. Allain H, Tribut O, Reymann JM, Polard E, Lecavorzin P, Bentue-Ferrer D: Perspectives médicamenteuses dans la maladie d'Alzheimer. Ann Med Interne 2001;152:527-532.
2. De Reuck J, Leys D, Bousser MG: Controverse: La démence vasculaire. Rev Neurol (Paris) 2001;157:338-343.
3. Carlson LA, Gottfries CG, Winblad B: Introduction (to vascular dementia). Dementia 1994;5:129.
4. Victoroff J, Mack WJ, Lyness SA, Chui HC: Multicenter clinicopathological correlation in dementia. Am J Psychiatry 1995;152:1476-1484.
5. De Deyn PP, Goeman J, Engelborghs S, Hauben U, D'Hooge R, Baro F, Pickut BA: From neuronal and vascular impairment to dementia. Pharmacopsychiatry 1999;32(suppl 1):17-24.
6. Kalaria RN, Ballard C: Overlap between pathology of Alzheimer's disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(suppl 3):S115-S123.
7. Jagust W: Untangling vascular dementia. Lancet 2001;358:2097-2098.
8. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Ama-ducci L, Orgogozo JM, Brun A, Hofman A: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43: 250-260.
9. Chui HC, Gonthier R: Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S124-S130.
10. Ferger D, Krieglstein J: Cerebral ischemia: Pharmacological bases of drug therapy. Dementia 1996;7:161-198.
11. Konno S, Meyer JS, Terayama Y, Margishvili GM, Mortel KF: Classification, diagnosis and treatment of vascular dementia. Drugs Aging 1997;11:361-373.
12. Lechner H: Status of treatment of vascular dementia. Neuroepidemiology 1998;17:10-13.
13. Nyenhuis DL, Gorelick PB: Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention and treatment. J Am Geriatr Soc 1998;46:1437-1448.
14. Roman GC: Vascular dementia today. Rev Neurol (Paris) 1999;155:64-72.
15. Sachdev PS, Brodaty H, Looi JCL: Vascular dementia: Diagnosis, management and possible prevention. Med J Aust 1999;170:81-85.
16. Roman G: Perspectives in the treatment of vascular dementia. Drugs Today 2000;36:641-653.
17. Meyer JS, Judd BW, Tawaklna T, Rogers RL, Mortel KF: Improved cognition after control of risk factors for multi-infarct dementia. JAMA 1986;256:2203-2209.
18. Meyer JS, Rogers RL, McClintik K, Mortel KF, Lofti J: Randomized clinical trials of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989;37:549-555.
19. Inzitari D, Erkinjuntti T, Wallin A, Del Ser T, Romanelli M, Pantoni L: Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 2000;903:510-521.
20. Lopez-Pouza S, Mercadal J, Marti-Cuadros A, Vilalta Franch J, Lozano-Gallego M: Triflusal in the prevention of vascular dementia: A pilot study. Drugs Today 1997;33(suppl C):45-50.
21. Walzl M: A promising approach to the treatment of multi-infarct dementia. Neurobiol Aging 2000;21:283-287.
22. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
23. The Lipid Study Group: Long-term effectiveness and safety of prevastatin in 9,014 patients with coronary heart disease and average cholesterol concentrations: The Lipid trial follow-up. Lancet 2002;359:1379-1387.
24. Schneider LS: Galantamine for vascular dementia: Some answers, some questions. Lancet 2002;259:1379-1387.
25. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M: Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997;28: 785-779.
26. Pasquier F, Leys D: Why are stroke patients prone to develop dementia. J Neurol 1997;244: 135-142.
27. Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia: The ischemic penumbra. Stroke 1981;12:723-725.
28. Bentue-Ferrer D, Decombe R, Saiag B, Allain H: Pharmacology of cellular ischemia. J Mal Vasc 1992;17:263-272.
29. Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA: Vasodilators in senile dementias: A review of the literature. Arch Gen Psychiatry 1979;36:220-223.
30. Schneider LS, Olin JT: Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-798.
31. Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, Wicke L, Neuhold A, Podreka I: Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-395.
32. Herrmann WM, Stephan K, Gaede K, Apeceche M: A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997;8:9-17.
33. Bes A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, Calvez R, Stehle B: A 24-month double-blind, placebo-controlled multicenter pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313-322.
34. Allain H, Bentue-Ferrer D: Effet de l'almitrine/ raubasine sur le métabolisme cérébral du sujet âgé. Press Med (Paris) 2002;31:562-564.
35. Herrmann WM, Stephan K: Moving from the question of efficacy to the question of therapeutic relevance: An exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. Int Psychogeriatr 1992;4:25-44.
36. Huber W: The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 1999;32(suppl 1):38-43.
37. Villardita C, Griolis S, Lomeo C, Cattaneo C, Parini J: Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology 1992;25:24-28.
38. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North-American EGb Study Group: A placebo-controlled, double-blind, randomized trial of an extract ofGinkgo bilobafor dementia. JAMA 1997;278:1327-1332.
39. Haase J, Halama P, Hörr R: Effectiveness of brief infusions withGinkgo bilobaspecial extract Egb 761 in dementia of the vascular and Alzheimer type. Z Gerontol Geriatr 1996;29:302-309.
40. EPMID: European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol 1996;36: 315-321.
41. Kittner B, for the European/Canadian Propentofylline Study Group: Clinical trials of propentofylline in vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S166-S171.
42. Treves TA, Korczyn AD: Denbufylline in dementia: A double-blind controlled study. Dement Geriatr Cogn Disord 1999;10:505-510.
43. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A: Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124-134.
44. Gonzales-Gonzales JA, Lozano R: A study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin. Rev Neurol 2000;30:719-728.
45. Spanish Group of Nicardipine Study in Vascular Dementia: An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia. Rev Neurol (Paris) 1999;9:835-845.
46. Denolle T, Sassano P, Allain H, Bentue-Ferrer D, Gandon JM: Effects of nicardipine and clonidine on cognitive functions and EEG in hypertensive patients. Fund Clin Pharmacol 2002;16:527-536.
47. Winblad B, Poritis N: Memantine in severe dementia: Results of the 9 M-Best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
48. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized placebo-controlled trial. Stroke 2002;33:1834-1839.
49. Fioravanti M, Yanagi M: Cytidine diphospho-choline (CDP choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2000;(4):CD000269.
50. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J: Effect of CDP choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann NY Acad Sci 1993;695:321-323.
51. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci 2002;203-204:141-146.
52. Robert P: Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: Focus on rivastigmine. Curr Med Res Opin 2002;18:156-171.
53. Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-169.
54. Mendez MF, Younesi FL, Perryman KM: Use of donepezil for vascular dementia: Preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999;11:268-270.
55. Pratt RD, Perdomo CA: Results of clinical studies with donepezil in vascular dementia. Am J Geriatr Psychiatry 2002;10(suppl 1):88-89.
56. Maelicke A: The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int J Clin Pract Suppl 2001;120:24-29.
57. Marder K: Efficacy of galantamine in probable vascular dementia. Curr Neurol Neurosci Rep 2002;2:389-390.
58. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359:1283-1290.
59. Parnetti L, Ambrosoli L, Agliati G, Caratozzolo P, Fossati L, Frattola L, Martucci N, Murri L, Nappi G, Puca FM, Poli A, Girardello R, Senin U: Posatirelin in the treatment of vascular dementia: A double blind multicenter study vs placebo. Acta Neurol Scand 1996;93:456-463.
60. Schück S, Bentue-Ferrer D, Lebreton S, Merienne M, Allain H: Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fund Clin Pharmacol 2002;16:57-65.
61. Nadeau SE, Malloy PF, Andrew ME: A crossover trial of bromocriptine in the treatment of vascular dementia. Ann Neurol 1988;24:270-272.
62. Allain H, Bentue-Ferrer D, Tribut O, Merienne M, Belliard S: Drug therapy of frontotemporal dementia. Hum Psychopharmacol Clin Exp, in press.
63. Allain H, Schück S: Neurological diseases; in Van Boxtel J, Santoso B, Edwards IR (eds): Drug Benefits and Risks. London, Wiley, 2001, pp 595-619.
64. Habeck M: New stroke therapies - hope for the future. Drug Discov Today 2002;7:157-159.
65. Bose B: Preservation of neuronal function during prolonged focal cerebral ischemia by ventriculocisternal perfusion with oxygenated fluorocarbon emulsion. Neurosurgery 1986;18:270-276.
66. O'Brien M: How does cerebrovascular disease cause dementia? Dementia 1994;5:133-136.
67. Leys D, Erkinjuntti T, Desmond DW, Schmidt R, Englund E, Pasquier F, Parnetti L, Ghika J, Kalaria RN, Chabriat H, Scheltens P, Bogousslavsky J: Vascular dementia: The role of cerebral infarcts. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S38-S48.
68. Suh GH, Shah A: A review of the epidemiological transition in dementia - cross-national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatr Scand 2001;104:4-11.